Kymera Therapeutics (KYMR) Competitors $44.48 -0.73 (-1.61%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$44.24 -0.23 (-0.53%) As of 07/11/2025 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYMR vs. RGC, VTRS, QGEN, ASND, BBIO, BPMC, VRNA, ROIV, ELAN, and RVMDShould you be buying Kymera Therapeutics stock or one of its competitors? The main competitors of Kymera Therapeutics include Regencell Bioscience (RGC), Viatris (VTRS), QIAGEN (QGEN), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Kymera Therapeutics vs. Its Competitors Regencell Bioscience Viatris QIAGEN Ascendis Pharma A/S BridgeBio Pharma Blueprint Medicines Verona Pharma PLC American Depositary Share Roivant Sciences Elanco Animal Health Revolution Medicines Regencell Bioscience (NASDAQ:RGC) and Kymera Therapeutics (NASDAQ:KYMR) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends. Do analysts recommend RGC or KYMR? Kymera Therapeutics has a consensus target price of $59.11, indicating a potential upside of 32.89%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kymera Therapeutics is more favorable than Regencell Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media favor RGC or KYMR? In the previous week, Regencell Bioscience and Regencell Bioscience both had 7 articles in the media. Kymera Therapeutics' average media sentiment score of 0.89 beat Regencell Bioscience's score of 0.60 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, RGC or KYMR? Regencell Bioscience has higher earnings, but lower revenue than Kymera Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRegencell BioscienceN/AN/A-$4.30MN/AN/AKymera Therapeutics$47.07M61.54-$223.86M-$3.10-14.35 Is RGC or KYMR more profitable? Regencell Bioscience has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -409.07%. Regencell Bioscience's return on equity of 0.00% beat Kymera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Regencell BioscienceN/A N/A N/A Kymera Therapeutics -409.07%-30.11%-25.65% Which has more risk and volatility, RGC or KYMR? Regencell Bioscience has a beta of 2.29, indicating that its share price is 129% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500. Do insiders & institutionals have more ownership in RGC or KYMR? 0.1% of Regencell Bioscience shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryKymera Therapeutics beats Regencell Bioscience on 7 of the 13 factors compared between the two stocks. Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KYMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYMR vs. The Competition Export to ExcelMetricKymera TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.90B$2.94B$5.56B$9.11BDividend YieldN/A2.45%5.07%4.01%P/E Ratio-14.358.8121.2120.54Price / Sales61.54292.00432.0899.78Price / CashN/A42.1137.1257.67Price / Book3.457.638.045.49Net Income-$223.86M-$55.05M$3.19B$250.45M7 Day Performance-0.74%8.43%3.63%4.79%1 Month Performance-5.94%5.42%4.06%7.68%1 Year Performance5.15%2.03%30.02%16.43% Kymera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYMRKymera Therapeutics3.1482 of 5 stars$44.48-1.6%$59.11+32.9%+14.1%$2.90B$47.07M-14.35170Analyst RevisionRGCRegencell Bioscience0.3692 of 5 stars$18.43-19.8%N/AN/A$11.37BN/A0.0010Gap UpHigh Trading VolumeVTRSViatris2.903 of 5 stars$9.20-1.3%$10.40+13.0%-18.5%$10.94B$14.74B-2.9032,000QGENQIAGEN4.0453 of 5 stars$47.49-1.8%$49.40+4.0%+20.4%$10.75B$1.98B119.075,765ASNDAscendis Pharma A/S3.6012 of 5 stars$175.98+1.0%$220.67+25.4%+28.9%$10.65B$393.54M-28.021,017News CoverageAnalyst ForecastBBIOBridgeBio Pharma4.6053 of 5 stars$43.50-1.1%$58.85+35.3%+72.8%$8.35B$221.90M-12.32400Analyst UpgradeBPMCBlueprint Medicines1.2242 of 5 stars$128.40+0.0%$128.25-0.1%+9.8%$8.29B$508.82M-51.98640Positive NewsInsider TradeVRNAVerona Pharma PLC American Depositary Share2.3804 of 5 stars$91.20-0.4%$107.36+17.7%+394.0%$7.79B$42.28M-45.6030Trending NewsAnalyst ForecastROIVRoivant Sciences2.8383 of 5 stars$10.74-2.3%$17.50+62.9%+1.1%$7.47B$29.05M-42.96860Analyst UpgradeELANElanco Animal Health1.5121 of 5 stars$14.48-1.1%$15.33+5.9%+9.0%$7.27B$4.44B19.579,000News CoverageRVMDRevolution Medicines4.5725 of 5 stars$36.67-3.2%$68.00+85.4%-12.3%$7.05B$11.58M-9.17250 Related Companies and Tools Related Companies RGC Competitors VTRS Competitors QGEN Competitors ASND Competitors BBIO Competitors BPMC Competitors VRNA Competitors ROIV Competitors ELAN Competitors RVMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KYMR) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
